Ladies and gentlemen, thank you for standing by. Welcome to the Scholarock 4th Quarter 2025 Financial Results and Business Update Call. At this time, all participants are on the listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you would need to press star 11 on your telephone. You will then hear an automated message advised and your hand is raised. And to withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would like now to turn the conference over to ScholarRock. Please go ahead.

Good morning. I'm Laura Ekes, Vice President of Investor Relations at ScholarRock. With me today are David Halal, Chairman and Chief Executive Officer, Akshay Vashna, President of R&D, Keith Wood, Chief Operating Officer, and VCAS Binha, Chief Financial Officer. During today's call, David will provide introductory remarks and a business update. Akshay will review our R&D progress. Keith will provide an update on our commercial readiness activities, and VCAS will provide a financial update. We will then open the call for questions. Before we begin, I'd like to remind you that during this call, we will be making various statements about Scholaroff's expectations, plans, and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any future date I encourage you to go to the investors in media section of our website for our most up to date SEC statements and filings with that I'd like to turn the call over to David David thank you Laura and good morning thanks to everyone for joining our fourth quarter and full year 2025 earnings call Scholarock is poised for a transformative year in 2026.

Our priorities are clear, and we are executing with focus, discipline, and urgency as we seek to deliver the world's first muscle-targeted therapy to children and adults living with SMA, while also laying the foundation to realize our ambition to develop life-transforming therapies for patients with additional rare and severe neuromuscular diseases globally. Our highest priority is to bring epitogramab to the SMA community as quickly as possible. We remain relentless on behalf of patients, and we are grateful that important progress continues to be made at a steady and rapid pace. Let me briefly summarize the key events that have occurred since our constructive and collaborative in-person type A meeting in November. First, a week following our type A meeting, the FDA issued a warning letter to Catalan, Next, Novo Nordisk rapidly responded to the FDA by mid-December. Then, following NOVO's response, FDA reached out prior to the holidays to schedule an early Q1 meeting. That meeting has since taken place, and importantly, at that meeting, the FDA had no additional request to NOVO's remediation plan. And most recently, following the meeting with NOVO, we were encouraged that the FDA sent the field team to Catalan, Indiana. At the conclusion of the visit, the FDA once again did not have any additional requests to NOVO's remediation plan and stated to NOVO that it intends to conduct a site re-inspection following routine manufacturing activities, which has since resumed in late February. The cadence of activity since our Type A meeting reflects the shared understanding between between us, the FDA, and Novo of the high unmet need in the SMA community and a shared sense of urgency to bring epitigromab to children and adults living with SMA as rapidly as possible. We are pleased with FDA's continued level of engagement, and we expect this momentum to continue. Our team is prepared to resubmit the epitigromab DLA following a successful FDA re-inspection of the Catalan, Indiana facility. We are reaffirming our guidance of BLA resubmission and U.S. launch following approval in 2026. Also, I am pleased that progress with a second till finish facility is moving quickly to build redundancy into our supply chain. Engineering runs at the facility are now underway with additional manufacturing runs to follow. we anticipate filing a supplemental VLA for the second filer later this year. As we advance the regulatory process for Epidogromab toward approval for patients with SMA in the U.S., our MAA review continues in Europe, and we expect a decision from the European Medicines Agency in mid-2026. With anticipated regulatory approvals in the U.S. and Europe this year, I would like to now turn to our Scholaroc commercial launch preparations. In the U.S., our team is deployed in the field and is educating potential prescribers and payers on the unmet need in SMA and the importance of targeting muscle, the principal organ affected in sma while also broadening and deepening relationships with the community in europe we are building momentum with launch readiness activities and engaging with the sma community we continue to plan for a launch in the second half of the year beginning with germany keith will discuss the substantial progress we are making with commercial preparation and our disease awareness initiatives shortly. We know it is not a matter of if, but when epitogramab will be approved for children and adults with SMA. We are emboldened by the commitment we have made to the more than 35,000 patients globally living with SMA who have received an SMN targeted therapy. We are working expeditiously to deliver on our ambition that globally, any patient with SMA who can benefit from Epidigromab should have access to Epidigromab. This is indeed what we know well and what we do well, and we are confident in the significant opportunity that we have to serve patients with SMA. We are ready, now more than ever, ever, to usher in the next era of innovation for the SMA community. I would like to now turn to the progress we are making in advancing our world-leading anti-myostatin pipeline. Enrollment and dosing continue in our Phase II Opal study evaluating epitigromab in infants and toddlers with SMA. Our IMD for epitigromab and FSHD is cleared, and we are on track to initiate a robust, randomized, placebo-controlled Phase II study later this year. With regards to our subcutaneous formulation of epitigromab, we share the promising results of a Phase I study comparing sub-Q and IV epitigromab in January. We expect to share our clinical and regulatory strategy for the program later this year. And finally, we continue to enroll and dose participants in our Phase I study for our highly innovative SRK439 myostatin inhibitor. We expect to have top-line data from this study in the second half of this year. OSHA will discuss these programs in greater detail shortly. Turning now to our balance sheet, we were pleased to have added, we are pleased to have ended 2025 with $368 million in cash and cash equivalents. This includes $60.4 million from the exercise of warrants that were set to expire on December 31st. We continue to strengthen our financial position to drive our commercial and R&D priorities, and this morning, we are pleased to announce that we have secured a new debt facility for up to $550 million, which the cost will discuss later in the call. 2026 will be a transformative year for Scholarok. We are ready to resubmit our BLA for epitogram abs at any moment. Our U.S. commercial team is working with urgency to prepare the market for the launch of the world's first and only muscle-targeted therapy for children and adults living with SMA. Beyond the U.S., the build-out of our 50-country operating platform is underway in Europe with other regions and countries to follow, and our highly innovative world-leading antimyostatin pipeline with epitogramab and SRK439 is progressing with strong momentum. The opportunity ahead of us to serve patients with SMA and additional rare and severe neuromuscular diseases is significant. We remain steadfast in our strategy, confident in the determination of our team, and energized by the transformative potential of epitogramab and our broader pipeline. The road ahead is one of purpose, progress, and extraordinary possibility. And with that, I'll now turn the call over to Akshay for an R&D update. Thank you, David.

And good morning, everybody. As David noted, we remain focused on our critical MAP BLA Registration to bring this important therapy to children and adults with SMA as rapidly as possible. Since being joined by Cure SMA and NOVO at our in-person type A meeting with FDA leadership in November, I've been pleased by the ongoing level of engagement and progress made on the art of patients. We expect this momentum to continue, and our team is prepared to resubmit the Citibramab DLA following a successful FDA reinfection of the Kaplan, Indiana facility. I'd now like to provide an update on the status of our second or finished facility, facility, which will strengthen supply continuity and support future commercial demand. As we shared late last year, we're working with a world-class, US-based manufacturing facility that has a proven track record of successful FDA and EMA site inspections. Importantly, engineering runs are now underway, with additional manufacturing runs planned to achieve two, and we continue to expect to submit a supplemental DLA with this facility later in 2026. Outside of the U.S., our epilogramab MAA is progressing through the review process with the EMA, and we continue to anticipate decisions in the middle of this year. Turning to our pipeline, let me start with the Phase II OPAL trial, evaluating epilogramab in infants and toddlers under the age of two. This trial is enrolling participants who have been treated with an SMN1 targeted gene therapy or who are receiving on-game treatment with The study is important for two reasons in particular. First, it is anticipated to expand the impact of opivimumab to the full spectrum of patients currently being treated for SMA, as this is the first time we're evaluating the use of opivimumab in dolganizma treated patients in a clinical trial setting. Second, we believe early intervention with opivimumab could support muscle during a critical early development phase complementing SMN-tylonal therapy that aim to preserve motor neurons. By promoting muscle growth from both motor neurons and muscle growth to maturing, epibromab has a unique opportunity to improve motor outcomes in the youngest patients with SMA to ensure that no patients are left behind. We continue to enroll patients in this study, and definitely long ago. Turning now to our next indication for a fibromat, fascio-scapular funeral muscular dystrophy, or FSHD. FSHD is a rare, devastating neuromuscular disease with significant unmet needs. More than 30,000 patients are diagnosed in the US and Europe alone, and there are no approved therapies. FSHD is caused by a dysregulation of DUTS4, a protein that can cause muscle damage when inappropriately expressed. Symptoms usually begin in adolescence or early adulthood with muscle weakness in the face and upper body, but FSHD can impact any muscle in the body. An estimated 20% of patients will become wheelchair-dependent. We are prioritizing FSHD as the next indication for a bit of a matter. First, there is significant unmet need in this population for a safe and effective therapeutic. Second, we have pre-clinical data from the Gold Standard Selected by the Small Mask Model that provides mechanistic rationale for a program in FSHD. Using this NASS model, we've shown that mystatin inhibition continues to robust increase in muscle mass, significant improvements in muscle force, and consistent gains in endurance after 28 days. Third, there are randomized studies in FSHD that suggest muscle mass can increase and have the capacity to show functional benefits. For example, in studies of either rigorous physical therapy or treatment with anabolic agents, patients with FSHD demonstrated increases in lean mass muscle function. These data suggest that epivomab, as a monotherapy, may have the potential to bring important benefits to FSHD patients. The FSHD IMD is clear, and our next step is to conduct a robust, randomized, double-blind placebo-controlled phase 2 study that is expected to enroll 60 patients. The study, or FORGE, is on track to initiate in the middle of this study. We will continue to advance two additional programs in our world-leading antigeniopathy pipeline, a sub-Q formulation of epitogramab and SRF A429. In our sub-Q epitogramab program, we showed some very exciting data from a phase-on study earlier this year. In that study, healthy volunteers received epitogramab at either 100 or 800mg sub-Q or 800mg IV. The data demonstrated that 800MIG SUBQ resulted in an overlapping pharmacodynamic profile with 800IV. Accordingly, SUBQ epigromat appears to have favourable via availability with the Pharmacodynamic Profile Administration. Additional development activities with SUBQ epigromat are underway, we are planning engagements with US and European regulators later in the year. Turning now to SRK-439, which we discovered by leveraging our world-leading expertise in targeting mice fappings. 439 is a subcutaneously-administered mice fappings inhibitor, binding to both pro- and latent mice fappings with high affinity. We recently presented data demonstrating that 439 is 10 times more potent than epivogamab, since we have shown in non-human primates that 439 can produce changes in whole-body lemab at doses as low. We're very excited about this program and boasting in our phase one health volunteer study. We expect to have top-line data. In closing, we're executing with focused urgency to bring a pin of the mouth to children and adults with SMA, whilst in parallel investing with discipline to advance our world reading and the strength of our data and the sustained momentum of our programs underpins our confidence that we can shape the future of treatment. I'll now turn the call over to Keith to discuss our commercial awards preparations. Keith?

Thanks, Akshay, and good morning, everyone. As David noted, our team continues to operate with urgency as we prepare for the launch of EpidograMap. Our commercial organization remains focused and disciplined, advancing the critical capabilities required to deliver a seamless launch and support patients from day one. Nearly a decade after the introduction of SMN-targeted therapies, the market continues to grow and and now represents nearly $5 billion in global annual sales. However, while SMN-targeted therapies have brought much-needed innovation, muscle strength and motor function remain the top unmet need, with 95% of patients continuing to experience persistent and progressive muscle weakness. That limits function and independence. Additionally, three-quarters of neurologists believe multiple modalities are necessary to optimally treat patients with SMA. This data underscores the significant opportunity we have with Epidagram App, the world's first muscle-targeted therapy. To this end, our U.S. customer-facing team is active in the field, focused on disease education programs that reinforce a broader understanding of SMA as a disease of the motor unit consistent of both the motor neuron and the muscle which is the principal organ impacted by the disease we continue to engage across approximately 140 SMA treatment centers 2,600 prescribing physicians and their multidisciplinary care teams throughout the U.S., and our SMA disease education efforts remain a core component of our work in the field. In parallel, we are strengthening and advancing the key elements of our commercial capabilities to ensure launch readiness. We have expanded our specialty pharmacy network to enhance SMA patient and caregiver convenience. SMA patients currently currently receiving an SMN-targeted therapy from a specialty pharmacy will be able to access epitogramab through that same specialty pharmacy. In addition, through our patient access partners, we have established a home infusion network of more than 10,000 affiliated nurses nationwide. We are also working to ensure we mitigate reimbursement and access bottlenecks. This includes preparations to launch our patient services program, which we have named Scholar Rock Supports. This program is designed to provide comprehensive and individualized support to patients, caregivers and providers. In addition, we remain focused on patient engagement and community activation. In January, we launched the next phase of our disease awareness campaign called Life Life Takes Muscle, aligned with our objective to deepen community awareness of the importance of targeting muscle. And finally, we continue to engage with payers, advancing discussions with national and key regional payers, as well as Medicare and Medicaid. At U.S. Approval and Launch, I look forward to discussing our comprehensive SMA Patient Access Support Program in more detail. While we make substantial progress in preparing for the launch in the U.S., we are also advancing launch readiness across key European markets in anticipation of a mid-2026 EMA decision. In Germany, we have established local leadership, initiated our Compassionate Use Program, and are progressing reimbursement planning to enable rapid access following approval. Across the broader region, we are advancing reimbursement dossiers in multiple countries, strengthening our distributor relationship, and we are building out our EMEA infrastructure to support future commercialization. In closing, we have invested thoughtfully to build the commercial foundation necessary to support a world-class launch, and we believe Epitigramab is well-positioned to play a central role in the next era of SMA care. Our team is prepared to move quickly upon approval and to deliver on our commitment to the SMA community, one patient, one caregiver, and one family at a time. With that, I'll turn the call over to Vikas. Vikas?

Thank you, Keith. Our financial objectives for 2026 remains consistent. We are focused on supporting our commercial bill to deliver a strong epitogomab launch, funding R&D activities to advance our pipeline and expand our leadership in the myostatin and muscle space, and continuing to evaluate opportunity to strengthen our balance sheet in a way that supports long-term shareholder value. In keeping with these objectives, I'm pleased to provide our fourth quarter and full-year financial results. For the fourth quarter, we reported $91.9 million in operating expenses, which included $19.4 million dollars in non-cash stock-based compensation. Excluding stock-based compensation, operating expenses were 72.5 million dollars. For the year ended 2025, we reported 384.6 million dollars in operating expenses, which included $75.6 million in non-cash stock-based compensation. Excluding stock-based compensation, operating expenses were $309 million for the year ended 2025. Turning to our balance sheet, we ended 2025 with $368 million in cash and cash equivalents. During the fourth quarter, we strengthened our cash position, adding $60.4 million from the exercise of warrants that were set to expire on December 31st. We continue to strengthen our balance sheet and are pleased to announce today that we secured a new debt facility for up to $550 million with blue-out capital. This debt facility consists of four elements. First, upon closing, $100 million was immediately available to us, which we have used to repay our prior $100 million debt facility with Oxford finance. Second, an additional $100 million is available to us this quarter, which we expect to draw down by March 31st. Then, following FTA approval of Apidigumab, we have the option to draw up to $150 million in additional capital. And lastly, we have an option for additional incremental facilities of up to $200 million at the mutual content of Scholarock and Blue House. This debt facility provides us with additional flexibility as we transition towards a global commercial space company while investing in our pipeline. In addition to the $150 million available from the debt facility upon FTA approval of Apidigomab, we will look to monetize our priority review vouchers to further strengthen our balance sheet. Looking ahead, we continue to operate with a tight financial plan. Our prioritized investment remains focused on our Apidigomab commercial launch readiness in the U.S. and Europe, strengthening our supply chain to support the pipeline and commercial demand for apetigromab, and advancing our highly innovative clinical program that Akshay discussed earlier in the call. With that, I will turn the call back to David.

Thanks, Vikas. In closing, we remain focused on bringing apetigromab, the world's first and only muscle-targeted treatment to improve motor function to children and adults living with SMA as rapidly as possible. We are encouraged by the progress that has been made and by the continued momentum across our regulatory, clinical, and commercial priorities. With a strong foundation, clear strategic priorities, and a world-class team, we are well positioned to make 2026 a transformative year for Scholarok as we continue to work with urgency on behalf of children and adults living with SMA. We look forward to updating you on our continued progress throughout the year, and with that, we'll now open the line for questions. Operator?

Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Again, we ask you please limit to one question and one follow-up. And our first question is going to come from Eric Schmidt with Kenner. Your line is open.

Thanks for a very comprehensive update. David, just to put a pin in it, is NOVO now ready for re-inspection, open for re-inspection? And then assuming the re-inspection does go, quote, well, what would trigger your resubmission?

What do you need to see from that re-inspection to be able to push the button on the refinement?

Thanks, Eric. So, you know, we are gratified, really, since our Type A meeting in November with the shared sense of urgency and high priority that both FDA and Novo has made the remediation of the Catalan-Indiana facility. and you got a sense from the call just the drumbeat of progress week after week month after month we like the high engagement we continue to see and given the constructive meeting in early q1 and then the following sites that really the gating item now just is a re-inspection follows these routine manufacturing activities as NOVO moves into full-scale production. As far as, you know, our trigger, we would look for inspection, as you noted, and we're assuming that given the progress that has been made, and that would then trigger. We are at the ready to submit our BLA, but it really would be with, you know, some level of And our next question will come from Tazeen Ahmed with Bank of America.

Your line is open.

Hi, guys. Good morning. Thanks for taking my question. Not to belabor the point on timing here, but I know you're confident about the ability of NOVO to resolve the issue. But in the event that you do have to revert to your backup facility, you've guided to a supplemental filing in the second half of the year. What would happen to timelines if that needed to be the primary filing?

Thanks, Tadeen, very much. As I noted on the call, we're gratified in the rapid and steady progress that has been made, you know, between FDA and Novo, and we do think epitigromab and the importance of epitigromab for the SMA community is a key driver in this, not the sole driver, but a key driver in this. I would say that we are pleased with how rapidly we are moving forward with an additional VILER. And our assumption is whether or not it were to be a supplemental VLA, which is our plan, or whether or not we had to fall back. We've always looked at that as an important effort on our part, no matter what, because we cannot control everything in this process. And we don't really believe that that timing would be altered tremendously in terms of if it were not an SPLA. So we've thought about it. It is our plan that it will be an SPLA. That's the level of insight, information, and confidence that we have. But nonetheless, we would be prepared to pivot should need be on behalf of children and adults living with SMA.

And our next question comes from Tess Romero with JPMorgan. Your line is open.

Hey, guys. Thanks so much for taking the question this morning. So first one is, can you elaborate on what it meant that the FDA sent a field team? What was the purpose of that? And is that routine? And then the second one, just to loop back on sort of better understanding the next procedural steps post the re-inspection and what the timelines could be there. Or will you get verbal communication or as written documentation what you'll see similar to a normal inspection?

Yeah, thanks, Tess. It's a good question because certainly nothing has been completely ordinary about this process. And I do think what has created some level of extraordinary behavior with kind of a constant drumbeat of progress I think it was really set off by that in-person type A meeting that we held with FDA and where there really was with cure SMA in attendance with NOVO in attendance there was a shared you know sense of urgency to bring epitigromab to patients and so while I can't comment on you know what was the overall sort of objective we do think what it shows is you know for just weeks after a really constructive meeting with Novo in early Q1 where there were no new requests by the FDA of Novo into their remediation plan we think it just continues to show high priority by the SEA to send a field team out to interact with the site and to indicate that you know after routine manufacturing activities which have since recommenced at the facility they would be in line for a re-inspection so overall we just feel good about the drumbeat of progress here and we're quite pleased and we would expect given these you know sort of rapid and steady pace that we've seen over these last three months, that anything else that follows the timing of a re-inspection, the timing of resubmission, that review, you know, hopefully it continues to follow sort of this commitment that has been made to rapidly progress the epitomab file so that we can deliver this drug to children and adults living with SMA. And we'll certainly keep you a prize on that progress.

Thank you. Thank you. And our next question comes from Manny for OHAR with Lyrinc. Your line is open.

Hey, guys. You have Ryan on for Manny. Thanks for taking our question, and congrats on the update. Maybe just one sticking with the review, kind of based off your latest conversations with the FDA, I'm curious what your expectations are for a turnaround time following BLA submission to eventual approval. You know, are there any Any details that still need to be worked out, label, et cetera, with regulators? And then maybe just as a second one on the pipeline, can you talk about the strategy for 439? Is this something that you plan to keep in-house, look for broader strategic options? Is it best suited in rare neuromuscular diseases or potential broader application?

Thanks, Brian. And regarding the timing, again, just to remind, you know, everybody tuning in today, in our CRL that we received last year, the sole approvability issue was the state of compliance at the Catalan Indiana facility. So, we're certainly very focused on working with FDA and Novo on that. As I noted earlier in the call, we would and we are planning and we are ready to rapidly resubmit our VLA following successful re-inspection. And again, we would just point to, without really being able to comment on timing, we would just kind of point to, you know, the evidence of the progress over these last three months and how attentive the FDA has been to remediating this facility and how focused Novo has been to really working with urgency as well. And we'll keep you apprised on that timing. Regarding the pipeline at 439, Asha? Yeah.

439, obviously, is a very important, exciting drug if the high-potency antimicrobial antibody appears to us, at least from the preclinical work, to be about tenfold more provenance. So it could be a very low-volume, small-volume, infrequent administration-type drug. So I think that creates very interesting of a space for us. We'll share a further development plan after we...

Thank you. And our next question is going to come from Kripa Devrakonda with Truist. Your line is open.

Hey, guys. Thank you so much for taking my question. Timelines-wise, not to belabor the point, you continue to expect inspection, VLA resubmission, U.S. launch, everything to happen in 2026. For the launch to be in 2026, can it still happen with a Class II submission? Are your diligence suggests that this is most likely going to be a Class II submission? And in any of your recent conversations with the FDA, was there any hint or indication for a potential CNPV for rapid deGromeda? Thank you.

I didn't get the last part of that, CRIPA. Could you say any indication?

The Commissioner's priority voucher. The national priority voucher.

These are all very good questions, CRIPA, and as you might imagine, we've thought about it all, right? And with all of the information that we have and the progress that is made we were pleased and confident to reaffirm the guidance that we provided today of a 2026 uh bla resubmission and u.s launch upon approval um we would uh certainly point to sort of this steady fda prioritization and progress with novo you know over these past weeks and and months and it remains you know very steady and I think like we have thought about class 1 versus class 2 and and what we've seen actually in our own sort of analysis of this even when class twos are sort of granted oftentimes a decision is taken up before that six-month timeline and and again I'm just reminding you that the sole approvability issue for us has been the status of the Catalan Indiana facility, and we're pretty – we are planning for the resubmission to be happening once we have indication that it was a successful re-inspection. So, we'll keep you apprised of that, but we certainly are very, very comfortable with the guidance that we have provided. And then regarding, like, the commissioners, sort of, I would just say that we are just staying in close communication with the FDA on all of our different initiatives and just keeping in the forefront the very high priority that exists with the FMA community in the United States to gain access to the world's first and only muscle-targeted treatment. and we look forward to continuing to keep you guys apprised on our regulatory progress there with FDA.

Great. Thank you so much.

Thank you. And our next question will come from Michael Yeh with UBS. Your line is open.

I'm not going to ask a submission question. Can you talk a little bit about the expectations for the label as it relates to either ambulatory, non-ambulatory, and with no issues regarding age subgrouping, given that you had what sounds like a very successful review process and only CMC was the outstanding part? How should we think about a broad label? And then a follow-up, assuming approval, maybe for Vakas, can you just remind us, given that your drug is a weight-based drug, how to think about the comparable pricing relative to other drugs and if models should reflect anything philosophically as it relates to the differences in how the drugs are administered.

Thanks, Michael. So, Akshay on the label and then, you know, Keith on the weight-based element of the drug and pricing.

Yeah, Michael. You know, we were gratified by what the progress made during the original production cycle. We had gone to a very calm stage with the drug label and the FDA had really worked hard With the chaplain issue being only the outstanding issue, we anticipate the drug certainly straight All of that being said, the details, ultimately, that's up to the FDA, but we know from the conversation leading up to the September release of the day that kind of guiding principles are what the FDA has shown before in the SMA space, the trial design, if you note that the totality of that package, we have experience with children two years and older, we have experience in patients. I think that...

Then on price, you know, I guess first of all, it's not really appropriate for us to comment on specifics at this stage, but I do promise you when we have approval and we have our launch call, we will get very specific. As you mentioned, you are going to see a range, so it's not going to just be three key facts, severity of S, nature of the disease. In combination with SMN-targeted therapies, our data from both Topaz and Sapphire have just demonstrated compelling clinical benefits. So, we will get into all of the specifics on pricing on the launch call.

Thank you.

Thank you. And our next question is going to come from Amy Lee with Jeffries. Your line is open.

Hi. Thanks so much for taking your question. So, looking ahead to launch, what commercial analogs would you point us to as we think about the initial uptake and launch trajectory? And then maybe another one on sub-QAPI. Do you think approval will require a full clinical study in SMA, a smaller bridging study, or primarily human factor studies, and if you could give us a timeline to market, that would be awesome.

Thanks very much, Amy, and yeah, what I would say is that, you know, for sure we've been pleased in our engagement with the patient community, the caregiver community, as well as, as Keith noted, neurologists' appreciation that not only addressing the motor neuron component of the disease, but for the first time to really be able to address directly the muscle component of the disease, which is a principal organ that is clinically impacted and affected by this disease. We sense that there is a lot of interest in accessing the drug, and that in and of itself could support a very nice uptake at launch. I think what Keith and I have looked at, though, is this is a, you know, essentially a Q4-week infusion. It will have a miscellaneous J-code for some period of time. We know that there are payers, for example, Medicaid, that could be a little sluggish at launch. We recognize payers in and of themselves. It's not a matter of if they reimburse, but sometimes it takes time to reimburse. And so we believe robust demand, but we think that will be met with initially some access speed bumps that could impact our launch curve. But overall, the long-term opportunity that we see for a Pinnacle map in the U.S. and beyond, we feel like is quite significant for us, and we're really looking forward to the eventual approval, and then Keith and team launching a pedigree map to the SMA community. With respect to your question on sub-Q and clinical regulatory strategy, I'll hand that over to Akshay.

Yeah, thanks, David. So for SUBQ program map, what we have is very interesting and supportive data that the SUBQ graph is viable, shows excellent bioavailability, and a function dynamic profile. Now we know a lot about program map in terms of PNPD from our prior work via the IV route administration. We also want to leverage that and find a path forward by saying, you know, this is a drug as well characterized in the study by different administrations, but if we can mimic the appropriate PKPD, then there's no reason why it could not be equally safe and effective. Now, those are all discussions that we need to have with the FDA. The initial improvementally...

Thank you.

Thank you. And our next question will come from Jeff Meacham with City Group. Your line is open.

Hey, good morning, guys. this is our way on for Jeff. Maybe just thinking about the second still-finished facility, if you guys were to switch over to that one, would it completely de-risk the supply chain from the U.S. and EU launch perspective? And then on the launch, you know, what specific leading indicators of payer and physician readiness are you guys tracking? Maybe if you guys can give some color on that to be helpful. Thanks.

Absolutely. I'll start with the second file and then Keith, you might need clarification on the second.

Yeah, can you repeat the second question, please?

Yeah, sure. What specific leading indicators are you guys paying attention to to indicate, you know, payer and position readiness that you're tracking? Great.

So second till finish, we are really pleased with the progress that we have been making as i mentioned uh you know tech transfer uh commenced in q4 engineering runs uh are underway uh and there are additional manufacturing runs followed here in the very near term so we're working urgently again our assumption is this is going to be our second miler we're going to submit an fbla um should we rely on this facility uh solely we we'd be risking as well, our U.S. So we wanted to be very thoughtful in selecting the right second of them.

So first of all, when it comes to the payers, you know, we've been really pleased with the access that our team has been able to get, as I stated in the prepared remarks, to not just the big national payers, but also now regional payers and even some Medicare and Medicaid. while we've had we've been able to have in-depth discussions with them and our medical team has been able to go through the sapphire clinical data with time is just as we've just as what's been shared in a lot of the cure SMA data and some of our own market research you know neurologists and patients they want more and they need more and that's why we understand three-quarters of these physicians already believe in multiple modalities to treat this to treat SMA Thank you.

And our next question will come from Salvatore Caruso with TD Cohen.

Hi, this is Salvatore Caruso on behalf of Mark Fram at TD. Thanks for taking my question. Just one quick question that kind of crossed some T's and got some I's regarding the status of the MMA review. Will that market also be served by the Novocatiland, Indiana facility? And if so, has the MMA taken any action in response to the FDA inspection findings?

Yeah. I can hand it over to Akshay. There is a mutual recognition between both FDA and EMA. And so this steady and rapid progress we're making with FDA actually serves us very well for the current MAA review with regulators. And so it's very important that we continue to make this progress forward. As I noted, the continued remediation and eventual, you know, successful re-inspection will really support our EMA decision near mid-year. And then, as I noted, if for some reason we were to rely on the second viler, that would also be very important. But for now, we're very excited with the rapid and steady progress that's been made. Akshay, anything?

Yeah, you covered it, David. I think the other piece will pull away those weeks.

Thank you.

Thank you, and the next question will come from Etzer Durot with Barclays. Your line is open.

Great. Thanks for taking the question. Just a couple for me. Has the FDA requested or could they request additional safety data that could extend review of a pedigree map? And then on FHSD, just wondered, would you be looking at any functional endpoints in the phase to study that you're planning, and could this be a more appropriate indication for SRK 39 longer term?

Thanks, Ed, sir. Yeah, it's a great comment, and we can remind you that DLA resubmission will be a fairly rapid and small resubmission, but there would be an update to sort of our safety database, which was called out in our response letter from the FDA. Akshay can comment on that, and then talk about any sort of functional outcome measures for FSHU.

Yeah, so we're in line with the FDA, the November meeting was useful in many regards, including that, and which aspect of the safety database needs to be updated, and so that's all agreed to, and so we're ready and prepared with this PLA resubmission. so I don't see any great issues there, but it's a good question, and I'm happy we should always provide the FDA with the latest safety understanding about drugs, which we will do. With respect to the forward phase 2 study in FSHD, the primary endpoint will focus on increasing the income of volume, but we will have on-state environment.

Thank you. Thank you, and our next question will come from Evan Sagerman with BMO Capital Markets. Your line is open.

Hi, Malcolm Hoffman on for Evan. Thanks for taking our question here. I was thinking about the financials of the business, and then you mentioned the new debt facility secured with approvals in U.S. and Europe coming this year. I just wanted to ask, how are you thinking about expectations for time to profitability and whether you anticipate any additional need for financing ahead of that kind of profitability hinge point? Thanks.

Thanks, Malcolm.

Hi, Malcolm.

You know, we're not given a forward-looking guidance at all here, but, you know, we will follow most likely the normal rare disease kind of revenue trajectory, which leads you to very similar levels of profitability kind of frames of two to three years from launch. but you know it also depends on how our pipeline progresses during that time and we will weigh into profitability versus investing into the future but overall looking at a fundamental principle of creating long term shareholder that we got.

Thanks Malcolm Thank you and our next question comes from Allison Retzel with Piper Sandler your line's open Hey, good morning, guys.

Thanks for taking the question. Just drilling down on some of the prior discussion around review timing, I know you've talked a lot about FDA's sense of urgency on EpidograMab. I guess, is there good precedent for FDA spending less than six months to review a Class 2 resubmission? And can you just clarify, does your guidance for commercial launch in 26 assume a Class 2 resubmission and the full six-month review? And then separately, just on OPAL, could you talk to what you're seeing on enrollment trends there and just, you know, what that tells you about the underlying awareness of a pentagram MAP in the SMA community?

Thanks, Allie. Maybe I'll just, you know, point out one example on the class two not taking the full-time. And I think it's important that we have been mentioned occasionally here during this current journey with Regeneron. And in 2023 at the same facility, Regeneron did have a CRL at a resubmission. I believe it was a class two resubmission. And yet it was approved within, you know, essentially a sort of a 60-day window. And so, but we have more examples than that. I just point to that because it's a little bit relevant given the fact that it was a CRL and it was the same facility, and I think it has to do with some assessment of the facility post and inspection. So I would just...

Yeah, following up on... What was the second question? Yeah, that's right.

The enrollment's going very well.

Well, I mean, I think the first thing to say, actually, is very wide knowledge, high, and consistent with that, they see the possibilities for this age range and disease severity range. We're gratified by the very nice, but yes, as we get later into the year, we'll clarify.

And the next question will come from Kalpet Patel with Wolf Research. Your line is open.

Guggenheim for COVID. Previous myostatin inhibitors in FSHD increased muscle mass without meaningful functional improvement. Can you get some color on how epitigromab aims to address this historical hurdle and what a clinically meaningful functional improvement might be in the planned phase two?

Sure.

Yeah. So I think you're pointing to either drug that didn't have a very clear and well-validated mechanism action.

I am showing no further questions at this time. This will conclude today's conference call. And thank you so much for participating. And you may now disconnect.